Clinical Implementation of Amyloid Neurodegeneration and Tau testing in Primary Care.

Recruiting

• Conditions: AD; Alzheimer's disease; 10012272

• Registration Number: NL-OMON56307
• Lead Sponsor: Vrije Universiteit Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 18 June 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 400

Inclusion Criteria

1) Present to primary care with cognitive complaints or behavioral change.
Either the patient him/herself, a caretaker / relative, the GP or elderly care
physician needs to be concerned.
2) Adequate fluency in Dutch to understand the informed consent and complete
questionnaires.

Exclusion Criteria

1) Age under 50.
2) Alcohol / drug abuse to such an extent that treatment would be advisable.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>1)Working diagnosis of the general practitioner in terms of:<br /><br>- Disease stage<br /><br>- Suspected etiology<br /><br><br /><br>2) Plasma biomarkers for Alzheimer's disease.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>1) Patient management decisions at baseline.<br /><br>2) Working diagnosis (defined as etiology and diseases stage) after 6 months.<br /><br>3) Patient/caregiver-reported cognitive complaints.<br /><br>4) Global cognitive functioning.<br /><br>5) Impairment in daily living.<br /><br>6) Qualitative evaluation of unmet needs in primary care that can be fulfilled<br /><br>by an AD blood test as defined by the practitioner.</p><br>